GliaCure Highlighted in ADDF Annual Report

GliaCure’s compound GC021109 and its successful Phase 1 clinical trial were highlighted in the Alzheimer’s Drug Discovery Foundation (ADDF) Annual Report, issued in late 2017. The report points out that there is growing research to suggest that anti-inflammatory approaches may hold the key to treating the underlying causes of Alzheimer’s disease, and shows that GC021109 is one of the few novel anti-inflammatory small molecules being developed; however, the report also makes clear the challenges for companies in the Alzheimer’s field, including regulatory hurdles, difficulties in trial recruitment, and lack of validated biomarkers. The full report can be found here.